All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Icosabutate
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: NST-4016
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 08, 2021
Details:
Icosabutate demonstrates potent anti-inflammatory, anti-fibrotic and antioxidant properties, and shows improvement in cardio-metabolic risk profile.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Icosabutate
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: Undisclosed
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: venBio Partners
Deal Size: $40.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing January 08, 2020
Details:
Proceeds will be used to progress the SEFA development pipeline: Completion of Ph 2b study of lead programme Icosabutate in (NASH) Initiation of clinical development of two new programmes for (PNALD)